Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Source: View publication →
In transplant-ineligible patients with newly diagnosed multiple myeloma, the addition of the anti-CD38 monoclonal antibody daratumumab to bortezomib, melphalan, and prednisone significantly improved progression-free survival and depth of response.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ALCYONE trial established daratumumab in combination with VMP as a highly efficacious, standard-of-care frontline regimen for older or transplant-ineligible patients with newly diagnosed multiple myeloma. It proved that adding a monoclonal antibody to a standard triplet backbone significantly deepens responses (including MRD negativity rates) and prolongs progression-free survival without compromising deliverability, signaling a paradigm shift toward quadruplet upfront therapies.
Historical Context
Historically, the standard of care for newly diagnosed multiple myeloma patients ineligible for autologous stem-cell transplantation consisted of doublet or triplet regimens such as VMP (bortezomib, melphalan, prednisone) or Rd (lenalidomide, dexamethasone). Daratumumab, a first-in-class human IgG1k monoclonal antibody targeting CD38, had already revolutionized the treatment of relapsed or refractory multiple myeloma as both monotherapy and in combinations (CASTOR and POLLUX trials). The ALCYONE trial was the first major phase 3 study to demonstrate its profound efficacy when moved into the first-line setting for transplant-ineligible patients.
Guided Discussion
High-yield insights from every perspective
Daratumumab is a monoclonal antibody targeting CD38, which was added to the VMP regimen in this trial. What are the primary mechanisms by which daratumumab induces myeloma cell death, and why is CD38 an ideal target in multiple myeloma?
Key Response
CD38 is a transmembrane glycoprotein highly and uniformly expressed on myeloma cells, but expressed at relatively low levels on normal lymphoid and myeloid cells. Daratumumab causes cell death via multiple mechanisms: complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), direct apoptosis upon cross-linking, and immunomodulatory effects such as the depletion of CD38+ regulatory T-cells and myeloid-derived suppressor cells (MDSCs).
In adding daratumumab to the VMP regimen for transplant-ineligible patients, what specific adverse events must a clinician be prepared to manage, particularly during the initial phases of therapy?
Key Response
Daratumumab is known for infusion-related reactions (IRRs), occurring in nearly half of patients, predominantly during the first infusion. Clinicians must administer premedication (corticosteroids, antipyretics, antihistamines) and use slow initial infusion rates. Additionally, the ALCYONE trial showed a higher rate of grade 3/4 infections (especially pneumonia) in the D-VMP arm, necessitating vigilance, potential antiviral prophylaxis (e.g., for herpes zoster), and consideration of IVIG for severe hypogammaglobulinemia.
The ALCYONE trial demonstrated the superiority of D-VMP over VMP; however, VMP is largely an older, predominantly European regimen. How does the choice of backbone (VMP vs. Rd as seen in the MAIA trial) influence your frontline management of transplant-ineligible multiple myeloma in modern practice?
Key Response
While ALCYONE proved the efficacy of adding daratumumab, the MAIA trial (Daratumumab plus lenalidomide and dexamethasone) has largely become the standard of care in the US. This is due to the continuous nature of lenalidomide/dexamethasone therapy compared to the fixed-duration, alkylator-heavy VMP regimen, avoiding melphalan-associated toxicity and leveraging the superior progression-free survival seen with D-Rd, pushing D-VMP to a secondary option in regions where lenalidomide is readily accessible.
The ALCYONE trial highlighted a dramatic increase in MRD negativity (at a threshold of 10^-5) when daratumumab was added to VMP. How should the achievement of MRD negativity in a highly frail, transplant-ineligible population guide our discussions regarding continuous versus fixed-duration therapy and potential de-escalation?
Key Response
While MRD negativity is strongly prognostic of PFS and OS, it is not yet standard practice to use MRD to stop therapy in frontline myeloma outside of clinical trials. The clinical challenge is determining whether pushing for deep responses (MRD-) justifies the added toxicity and financial burden of continuous daratumumab in older, frailer patients, and whether achieving sustained MRD negativity might eventually serve as a biomarker to safely de-escalate or pause therapy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The trial utilized progression-free survival (PFS) as the primary endpoint. From a methodological standpoint, what are the limitations of using PFS and overall survival (OS) comparisons in a trial with a continuous therapy arm (daratumumab maintenance) versus a fixed-duration control arm (VMP alone)?
Key Response
Comparing a continuous intervention (D-VMP followed by daratumumab maintenance until progression) against a fixed-duration control (VMP for 9 cycles then observation) inherently biases longer-term endpoints like PFS in favor of the continuous arm. It prevents researchers from distinguishing whether the benefit is derived from the synergistic D-VMP induction or simply the effect of single-agent daratumumab maintenance delaying progression.
As a peer reviewer evaluating the internal validity of the ALCYONE trial, how does the asymmetry of the post-induction treatment phase between the two arms threaten the study's ability to isolate the specific benefit of quadruplet induction?
Key Response
A rigorous reviewer would flag that the experimental arm received D-VMP followed by continuous daratumumab, while the control arm stopped VMP after 9 cycles with no maintenance or placebo. Because the control arm lacked a maintenance phase, it is impossible to determine if the massive PFS benefit is driven by deep responses from the upfront quadruplet combination or merely the continuous suppression of disease by ongoing daratumumab monotherapy.
Based on the ALCYONE and MAIA trial results, how should NCCN and ESMO guidelines classify CD38-directed therapies for transplant-ineligible newly diagnosed multiple myeloma, and what level of evidence supports displacing traditional doublets (e.g., Rd or Vd) from Category 1 preferred status?
Key Response
NCCN and ESMO updated their guidelines to include D-VMP and D-Rd as Category 1, preferred options for transplant-ineligible NDMM based on unprecedented PFS and OS benefits. The standard of care has definitively shifted from doublets to triplets (D-Rd) or quadruplets (D-VMP) for patients who can tolerate them, supported by high-quality randomized phase 3 data, reserving older doublets only for highly frail populations who cannot tolerate multi-agent regimens.
Clinical Landscape
Noteworthy Related Trials
VISTA Trial
Tested
Bortezomib, Melphalan, and Prednisone (VMP)
Population
Newly diagnosed, transplant-ineligible multiple myeloma patients
Comparator
Melphalan and Prednisone (MP)
Endpoint
Time to progression
CASTOR Trial
Tested
Daratumumab, Bortezomib, and Dexamethasone (D-Vd)
Population
Patients with relapsed or refractory multiple myeloma
Comparator
Bortezomib and Dexamethasone (Vd)
Endpoint
Progression-free survival
MAIA Trial
Tested
Daratumumab, Lenalidomide, and Dexamethasone (D-Rd)
Population
Newly diagnosed, transplant-ineligible multiple myeloma patients
Comparator
Lenalidomide and Dexamethasone (Rd)
Endpoint
Progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis